OmniAb stock kpis
Want to see OABI full AI Analyst Report?
Approved Products
OmniAb reported approved products of 3 in Q3 2026, unchanged from Q2 2026 and unchanged year over year. The highest value was 3 in Q4 2022.
Counts products that have obtained regulatory approval and can generate recurring sales or royalties, serving as the clearest proof of the platform’s commercial success. Approved products typically convert into steadier revenue and de-risk the business model, while few or no approvals underline reliance on future clinical progress.
Approved Products has been unchanged for years, indicating OmniAb hasn't added new regulatory approvals to its royalty-bearing portfolio; recent revenue strength therefore stems from upfront/milestone receipts and instrument sales rather than growth in licensed, revenue-generating approved drugs. Management touts expanding clinical programs and rapid phase jumps that create meaningful future upside, but until those programs convert to approvals, revenue will remain lumpy and tied to partner timelines—upside is milestone-led, not recurring royalty-driven.
OABI Approved Products
| Period | Approved Products |
|---|---|
| Q3 2026Sep 30, 2026 | 3 |
| Q2 2026Jun 30, 2026 | 3 |
| Q1 2026Mar 31, 2026 | 3 |
| Q4 2025Dec 31, 2025 | 3 |
| Q3 2025Sep 30, 2025 | 3 |
| Q2 2025Jun 30, 2025 | 3 |
| Q1 2025Mar 31, 2025 | 3 |
| Q4 2024Dec 31, 2024 | 3 |
| Q3 2024Sep 30, 2024 | 3 |
| Q2 2024Jun 30, 2024 | 3 |
| Q1 2024Mar 31, 2024 | 3 |
| Q4 2023Dec 31, 2023 | 3 |
| Q3 2023Sep 30, 2023 | 3 |
| Q2 2023Jun 30, 2023 | 3 |
| Q1 2023Mar 31, 2023 | 3 |
| Q4 2022Dec 31, 2022 | 3 |

